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Abstract: Inflammation plays a role in the initiation and development of many types of cancers,
including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a type of
EOC. There are connections between EOC and both peritoneal and ovulation-induced inflammation.
Additionally, EOCs have an inflammatory component that contributes to their progression. At sites
of inflammation, epithelial cells are exposed to increased levels of inflammatory mediators such as
reactive oxygen species, cytokines, prostaglandins, and growth factors that contribute to increased cell
division, and genetic and epigenetic changes. These exposure-induced changes promote excessive cell
proliferation, increased survival, malignant transformation, and cancer development. Furthermore,
the pro-inflammatory tumor microenvironment environment (TME) contributes to EOC metastasis
and chemoresistance. In this review we will discuss the roles inflammation and inflammatory
mediators play in the development, progression, metastasis, and chemoresistance of EOC.
Keywords: inflammation; epithelial ovarian cancer; cytokines; reactive oxygen species; growth factors
1. Inflammation and EOC
Inflammation is part of the immune response that protects against foreign pathogens and aids
in healing. Inflammation is elicited in response to cellular damage either by infection, exposure
to foreign particles (pollutants or irritants), or an increase in cellular stress [1]. The ultimate goal
of the inflammatory response is to restore tissue homeostasis, either by destruction or healing of
the damaged tissue. The acute or immediate inflammatory response involves modification of the
vasculature surrounding the site of stress or damage to increase blood flow. This alteration is then
followed by activation of innate immune cells already present in the tissue, including macrophages,
dendritic cells (DC), and mast cells, and an increase in infiltration of additional innate immune cells
into the affected tissue. At sites of inflammation there are high levels of reactive oxygen species (ROS),
cytokines, chemokines, and growth factors that are produced by the immune cells and other cells in the
tissue. Acute inflammation is essential for tissue homeostasis and to protect against normal exposure
to pathogens. However, in certain cases the body is unable to resolve this response or is subjected to
repeated stimulation resulting in chronic inflammation.
Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths in women in the United
States [2] and can originate in the germ cells, sex-cord stroma, the fallopian tube (FT), or ovary
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epithelium. Epithelial ovarian cancer (EOC) which originates from the ovary or fallopian tube
epithelium, accounts for 85–90% of all OCs. Chronic inflammation is an important risk factor associated
for EOC and high grade serous ovarian cancer (HGSC), the most malignant subtype of EOC. Chronic
inflammation results in activation of signaling pathways, transcription factors, and the innate and
adaptive immune responses [3,4]. In this review we primarily focus on inflammation as a risk factor
for invasive EOC, but have also included supportive evidence from other OC subtypes, studies that do
not define the subtype of OC, and other tumor types as indicated.
1.1. Signaling Pathways and Transcription Factors
Several signaling pathways and transcription factors involved in the inflammatory response also
play critical roles in EOC. Here we briefly introduce relevant pathways that will be linked to OC
formation in later sections. Cytokines produced during inflammation bind to and activate toll like
receptors (TLRs) on cell surfaces, which results in activation of the signaling pathways involving
mitogen-activated protein kinases (MAPKs) p38 and JNK (c-Jun N-terminal kinase) and transcription
factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the signal
transducer and activator of transcription (STATs). The MAPK pathway regulates cellular processes
like proliferation, differentiation, growth, migration, and cell death by upregulating the expression
of transcription factors like AP-1, c-Jun, FOS and by activating NF-κB and STATs, that either by
themselves or along with AP-1 or c-Jun regulate expression of pro-survival and pro-growth genes.
NF-κB and AP-1 also regulate production of cytokines like IL-6 [5–7].
During inflammation these transcription factors play an important role to maintain tissue
homeostasis. However, in case of chronic inflammation, the signaling pathways are continuously
stimulated, which can contribute to tumorigenesis.
1.2. Innate Immune Response
Inflammation activates the innate immune response, which signals macrophages and DCs
to secrete chemoattractants like Interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1),
and various other inflammatory mediators. These chemoattractants in turn result in recruitment
of neutrophils, lymphocytes, and natural killer (NK) cells to the site of damage. All of these cells
then secrete cytokines like IL-1, IL-3, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), interferon (IFN)
α, and colony-stimulating factors (CSF) like granulocyte macrophage CSF (GM-CSF). The cytokines
bind to transmembrane receptors on the cell surfaces of other cells to activate transcription factors
that regulate gene expression downstream of the cytokine activated pathway. This creates a
pro-inflammatory environment resulting in recruitment of other immune cells, migration of endothelial
cells, and proliferation of fibroblasts. Activation of macrophages and NK cells results in the production
of high levels of ROS and reactive nitrogen species (RNS), which are used by these cells to kill foreign
pathogens, but also end up damaging neighboring normal cells [8]. The lymphocytes also secrete
growth factors like platelet derived growth factor (PDGF), transforming growth factor beta (TGF-β),
and fibroblast growth factor (FGF), which facilitate wound healing. Overall the acute immune response
is a rapid response that typically only lasts a few days. It results in removal of the pathogen, release of
proteolytic enzymes to destroy damaged tissue, or stimulation of the proliferation of fibroblasts and
epithelial cells to repair the tissue [1].
1.3. Adaptive Immune Response
If the infection is not resolved by the innate immune response, the adaptive immune response
is activated, which is less inflammatory in nature. The adaptive immune response also provides
longstanding protection against specific pathogens and/or antigens. B cells and T cells are the
effector cells of the adaptive immune system that are derived from lymphocytes when they are
presented with specific antigens by the antigen presenting cells (APC). T cells respond to the APCs by
producing IL-2, which induces expression of transcription factors that facilitate T cells to differentiate
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into T regulatory (Tregs) and T effector (Teff) cells. There are two major classes of T effector cells;
CD8+ cytotoxic T cells and CD4+ T helper (Th) cells. Th cells are further differentiated into Th1, Th2,
or Th17 depending on the ILs secreted and the transcription factors expressed. IFN-y activates STAT1
to induce formation of Th1 and IL-6, and TGF-β can induce Th17 cell formation. Th1 and Th17 secrete
ILs and activate macrophages and B cells to create a pro-inflammatory microenvironment (ME) that
can be protumorigenic depending on the context. Tregs are immunosuppressive cells that turn off the
immune response [1,9,10].
2. Inflammation as a Risk Factor for EOC
Amongst other factors such as hereditary, environmental, and lifestyle, inflammation emerges
as an important risk factor for EOC. EOC arises either in the epithelial layer surrounding the ovary
or in the epithelium of the distal FT, which could then spread to the ovary. A significant portion
of HGSC is thought to originate in the FT, in part because removal of the FT significantly reduces
OC risk [11]. Interestingly, while surgical specimens from mutation carriers rarely had premalignant
ovarian epithelial changes, early lesions called serous tubal intraepithelial carcinomas (STICs) were
found in the FTs of 5–10% of the patients. Copy number and mutational analysis suggest that STICs
shed cells with metastatic potential that then colonize the ovary to form HGSC. STICs are mostly
found in the fimbriae, the distal end of the FT that shares a ME with the ovary. During a woman’s
lifetime, the repeated secretion of ROS, cytokines, and other growth factors by the ovaries and immune
cells creates a chronic inflammatory ME in the peritoneum that in turn potentiates the initiation of
normal cells to malignant ones in the FT and the ovary, supports tumor progression, metastasis,
and development of resistance to chemotherapy.
During ovulation, infection and other causes of inflammation ovary and FT tissue is damaged and
undergoes repair. We will briefly discuss how each of these processes evoke or involve an inflammatory
response that can persist, leading to a cytokine and growth factor rich environment in the peritoneum
and contribute to EOC.
2.1. Ovulation
The process of ovulation itself is comparable to that of inflammation as described in the early 20th
century. The development of the follicle to its rupture and release of the egg results in recruitment of
activated immune cells to the ovary and production of enormous amounts of chemokines, cytokines,
and growth factors. Ovulation is initiated by a surge of Luteinizing hormones (LH) that results in
increased blood flow to the ovarian follicles. Before release of the egg, the surge of LH hormone recruits
neutrophils and macrophages to the graafian follicles [12–14]. Macrophages in the theca have been
shown to support growth of follicles [15]. During ovulation macrophages secrete growth factors like
hepatocyte growth factor (HGF), TGF-β, and epidermal growth factor (EGF), which stimulate cellular
proliferation and follicle growth. Simultaneously the macrophages also secrete ROS, TNF-α, and IL1β,
which stimulate local apoptosis resulting in rupture of the follicle, which bathes the ovarian surface
and fimbriae with follicular fluid. Exposure of FT cells to follicular fluid results in altered expression
of genes associated with inflammation, including increased expression of IL8 and cyclooxygenase-2
(COX-2) [16]. Quiescent fibroblasts are present in the thecal layer surrounding the follicles. Exposure
to growth factors stimulates their proliferation and they then secrete prostaglandins, collagenases,
and plasminogen activator. In the corpus luteum, after the follicle is released, the macrophages secrete
prostaglandins, ROS, and TNF-α, which stimulate apoptosis of the corpus luteum cells. Therefore,
ovulation results in the cyclic exposure of FT and ovarian epithelial cells to high levels of ROS,
cytokines, and growth factors [17] Although the other causes of inflammation discussed below are
important and result in increased overall risk for EOC, the process of ovulation itself occurs often in
the lifetime of the majority of women and may be the most important inflammation-related risk factor
for EOC. This hypothesis is corroborated by the laying hen model, which is commonly used to study
ovarian cancer [18]. In this model, hens develop spontaneous EOC, likely due to their high ovulation
Cancers 2018, 10, 251 4 of 30
rate, thus linking ovulation directly as an increased risk factor for EOC. Delayed onset of menarche
and early onset of menopause have been shown to be inversely related to the risk of OC, likely due
to the reduction in number of ovulation cycles in a woman’s lifetime [19,20]. Further, ovulation has
also been connected to EOC because contraceptive pills, pregnancy, and breastfeeding reduce the
risk of OC. These factors reduce, halt, or delay overall ovulation cycles, respectively, which in turn
reduces overall exposure to inflammation of the ovary and FT. The associations of parity and oral
contraceptive use with invasive EOC were recently confirmed in a large, prospective study using
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort that found only
limited heterogeneity in the risk between reproductive factors and EOC subtypes [21]. Hysterectomy,
tube ligation, and removal of ovaries are also protective against development of OC [22,23].
2.2. Infection
Pelvic inflammatory disorder (PID) is the infection of the female reproductive organs like cervix,
uterus, FTs, and ovaries. It is a significant risk factor for OC and is caused by various bacteria and virus
such as Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papilloma virus,
and cytomegalovirus [24,25]. Infection by these microbes results in DNA damage and production of
ROS and induces a pro-inflammatory response, which involves secretion of cytokines and migration of
immune cells [24]. PID is generally resolved with antibiotics within 48–72 hours of detection. However,
repeated infection and unresolved inflammation can lead to chronic inflammation that is a risk factor
for EOC.
2.3. Other Sources of Inflammation
The other causes of inflammation in the ovaries and/or FTs are endometriosis, obesity, Polycystic
Ovarian Syndrome (PCOS), and talc exposure. Endometriosis is defined as presence of stroma and
endometrial gland tissues in the pelvic peritoneum, rectovaginal septum, and ovaries [26]. Retrograde
menstruation is the most commonly accepted theory for endometriosis. Retrograde menstruation
results in aberrant accumulation of red blood cells (RBCs) and tissue, which can trigger an inflammatory
response, activating the macrophages in the peritoneal cavity [27,28]. The macrophages lyse the
RBCs, resulting in an increase in iron accumulation in the endometric implants and peritoneal fluid.
The accumulated iron can catalyze formation of free radicals like RNS and ROS in the peritoneum
and results in increased oxidative stress (OS). OS can activate NF-κB, in macrophages resulting in
secretion of growth factors, cytokines, and IFNs. Around one third of women are affected by mild
endometriosis, which resolves on its own over time. For the remaining cases, endometriosis results in
chronic pain and inflammation, which can be resolved by excision of affected tissue or the outgrowth.
However, in 45% of these cases, the endometriosis reoccurs resulting in repeated bouts of chronic
inflammation [29,30].
Obese women have higher risks of EOC and HGSC and pro-inflammatory cytokines are associated
with higher body mass index (BMI) levels. Adipose tissues secrete the cytokines TNF-α, IL-6, IL-8,
and MCP-1, which can induce an inflammatory reaction in the peritoneum [31]. Continuous secretion
of these cytokines leads to a state of chronic inflammation, which includes activation of macrophages
and recruitment of NK cells and results in high levels of OS. Once the tumor has been initiated,
the continuous secretion of cytokines by adipose tissue or omentum can facilitate migration of cancer
cells to the omentum, promoting metastasis of the tumor into the peritoneum [30]. High levels
(>10 mg/L) of C-reactive protein (CRP), a marker of global inflammation, are associated with an
increased risk of EOC [32,33]. IL-6 itself is not a risk factor for EOC but in obese women IL-6 and CRP
may be associated with increased EOC risk [33].
PCOS also contributes to inflammation in women and may increase risk of EOC [34]. PCOS
is a hormonal disorder occurring in reproductive aged women during which ovaries may develop
numerous small collections of fluid and fail to release eggs properly. Obesity, hyperandrogenism,
and increased insulin resistance further characterize PCOS. Increased C-Reactive protein (CRP) and
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MCP-1 levels, indicative of low-level chronic inflammation, are elevated in women with PCOS [35–38].
Simultaneously chemokines like IL-18, IL-6, and TNF-α are also increased in circulation in women with
PCOS [39–42]. The increase in inflammatory mediators correlates positively with BMI, suggesting that
increased obesity in women with PCOS may be the source of inflammation. Increased DNA damage
and OS is observed in women with PCOS, which may also increase risk for EOC [43]. Evidence linking
PCOS directly to EOC is limited due to small study sizes, PCOS being associated with other EOC risk
factors such as obesity, and PCOS possibly being only associated with one subtype of EOC, borderline
serous [44].
Talc is a silicate mineral and exposure to it can cause inflammation of the ovaries and poses a
risk hazard for development of EOC [45]. It has been proposed that talc from talcum powder used
for dusting and from condoms and vaginal diaphragms can migrate up to the ovaries via retrograde
flow of fluids and mucous and get lodged in the ovaries. Tubal ligation, which is protective for EOC,
is thought to block the transport off talc from the lower genital tract. Talc behaves as a foreign particle,
triggering an inflammatory response [46,47]. The talc attracts macrophages, which try to phagocytose
it. The macrophages then send chemotactic signals to other immune response mediators and initiate a
wound healing process. Since talc is not degradable by the body, it inhibits the wound healing process,
resulting in chronic inflammation.
2.4. NSAIDS and Reduced Risk of EOC
Further connecting inflammation to EOC are several studies that demonstrate that intake of
non-steroidal anti-inflammatory drugs (NSAIDs), specifically of aspirin, correlates inversely with risk
of OC and endometrial cancer [48–52]. In vitro studies with OC cell lines and NSAIDS show that
NSAIDs and COX-2 inhibitors facilitate apoptosis, however this effect is not dependent on COX-2
and may be due to upregulation of p21, a protein important for cell cycle arrest [53]. Another study
by Arango et al., demonstrates that acetylsalicylic acid or aspirin resulted in increased apoptosis via
downregulation of Bcl2 in an endometrial cancer cell line [54]. A third study has shown that a selective
COX-2 inhibitor, JTE-522, can inhibit proliferation and increase apoptosis of endometrial cancer cells
by increasing levels of p53 and p21 and decreasing phosphorylation of retinoblastoma (Rb) protein,
which results in its activation; all of which results in cell cycle arrest [55,56]. Simultaneously, there was
an increase in caspase-3 activity, which is indicative of increased apoptosis. Another mechanism by
which aspirin could facilitate its chemopreventive nature is by inhibiting oxidative induced DNA
damage [57]. COX-1 is also expressed in normal ovaries of the laying hen, with expression increasing
in post-ovulatory follicles suggesting its importance for or a role in ovulation. With the onset of
OC, COX-1 expression is increased [58] and COX-1 inhibition and NSAIDs have shown to decrease
proliferation of ascites in the laying hen OC model [59]. Further, when 0.1% aspirin was included
in their diet for one year, although the onset of OC was not different, the progression of cancer was
slower when compared to hens fed with regular diet [60].
As discussed, inflammation results in secretion of ROS, growth factors, cytokines, and chemokines
into the shared environment surrounding the ovary and distal FT. Exposure of normal tissue to
these inflammatory mediators results in activation of downstream signaling that can promote the
transformation of normal cells or survival of already transformed cells. Once EOC has already
formed further exposure of cancer cells to these inflammatory mediators also results in activation of
downstream signaling within the cancer cell and in the surrounding tissue, creating an inflammatory
environment that can further promote EOC (Figure 1). We will discuss in more detail how key
inflammatory mediators contribute to EOC initiation, progression, metastasis, and chemoresistance.
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exhibit a high number of chromosomal aberrations and genomic instability [62]. The most common 
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DNA damage response [63]. A pro-inflammatory ME can also contribute to genetic instability and 
therefore play a role in EOC cancer initiation. A pro-inflammatory ME, which is continuously 
supplemented by ROS, cytokines, and growth factors, can cause DNA damage in epithelial ovarian 
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cells transformed either by oncogenic alterations or by exposure to inflammation are in a pro-
inflammatory ME they are able to turn on pro-survival signaling pathways rather than the senescence 
pathways that are normally induced by oncogene expression in normal cells. For example, disruption 
of the RAS pathway results in activated NF-κB signaling and upregulation of its downstream targets 
including cytokines like IL-1β, IL-6, and IL-8. These cytokines are upregulated in EOC patients and 
their increased levels correlate with decreased survival [64–71]. The inflammatory mediators like 
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Figure 1. Sources of inflammation in the ovary and fimbriae. Ovulation, retrograde menstruation,
endometriosis, infections, exposure to talc, Polycystic Ovarian Syndrome (PCOS), and obesity result
in exposure of the ovary and fimbriae to reactive oxygen species (ROS), oxidative stress, cytokines,
and growth factors, generating an inflammatory response that leads to additional production of ROS
and cytokines in the ovary. Unresolved, chronic inflammation is a critical risk factor for tumor initiation.
3. Inflam ation and EOC Initiation and Progression
Tumorigenesis is a multistep process that requires cells to gain the ability to evade apoptosis and
antigrowth signals, proliferate independently of stimuli, develop a support system (angiogenesis),
and have the capacity to invade and metastasize. Tumorigenesis is initiated by the transformation of a
normal cell to a malignant one. The deregulation of the above mentioned processes in the malignant
cell could potentiate its progression to cancer.
One mechanism of cancer initiation is genomic instability due to DNA damage [61] and EOCs
exhibit a high number of chromosomal aberrations and genomic instability [62]. The most com on
gene mutations in HGSCs include BRCA, TP53, and genes in involved in mismatch repair and the DNA
damage response [63]. A pro-inflammatory ME can also contribute to genetic instability and therefore
play a role in EOC cancer initiation. A pro-inflammatory ME, which is continuously supplemented
by ROS, cytokines, and growth factors, can cause DNA damage in epithelial ovarian and FT cells,
switch on antiapoptotic pathways, and initiate transformation of normal cells. When cells transformed
either by oncogenic alterations or by exposure to inflammation are in a pro-inflammatory ME they
are able to turn on pro-survival signaling pathways rather than the senescence pathways that are
normally induced by oncogene expression in normal cells. For example, disruption of the RAS
pathway results in activated NF-κB signaling and upregulation of its downstream targets including
cytokines like IL-1β, IL-6, and IL-8. These cytokines are upregulated in EOC patients and their
increased levels correlate with decreased survival [64–71]. The inflammatory mediators like cytokines,
chemokines, growth factors, and prostaglan ins secreted by the transformed epithelial cells further
promote a pro-inflammatory environ ent, which can reprogram the surrounding cells to form the TME.
The TME is mainly composed of endothelial cells, cancer associated fibroblasts (CAFs), adipocytes,
tumor associated macrophages (TAMs), regulatory T-cells, pericytes, infiltrated immune cells such as
neutrophils, lymphocytes, and various other cells that further secrete growth factors and cytokines
which potentiate tumor progression (Figure 2, Table 1). Furthermore, OC-initiating cells (OCICs)
have been identified in tumors and ascites that exhibit stem cell like properties and are ca able of
forming tumors [65,66,72]. Cytokines can promote self-renewal of CD133+ OCICs to potentiate tumor
progression [73].
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Figure 2. Inflammatory mediators contributing to EOC progression, metastasis, and angiogenesis.
EOC cells produce ROS, chemokines, cytokines, and growth factors that can: (1) Lead to recruitment of
immune cells like Dentric cells (DC), Natural killer cells (NK), Tumor associated macrophages (TAMs),
and T-regula ry (Treg) cells i to the TME, which gen rate additional cytokines, ROS, and growth
factors, resulting in chronic inflammation. (2) Stimulate the tumor cells themselves, the TAMs, and the
surrounding fibroblasts (also known as cancer associated fibroblasts or CAFs) to proliferate and secrete
growth factors like TGF-β and FGF that stimulate production of integrins and Matrix Metalloproteins
(MMPs), resulting in migra ion of he tumor cell via degr datio of he extra cellular matrix (ECM).
(3) Stimulate endothelial cells (EC) to produce growth factors like PDGF and EGF and factors like
VEGF that stimulate angiogenesis. The double arrows indicate that the cells are a source of the factor
as well as stimulated by it.
The innate immune response can prevent tumorigenesis by recognizing and eliminating
transformed cells. However, chronic inflammation can contribute to the ability of premalignant
cells to evade apoptosis, escape the immu e surveilla ce, and continue to gr w, resulting in tumor
formation. As mentioned, EOC can originate from either distal FT or ovarian epithelial cells. Since both
the ovary and fimbria are exposed to the same ME, exposures reviewed here are relevant to initiation
in either tissue. [74]. In this section we will review the role of OS and some specific pro-inflammatory
mediators and signaling pathways in the initiation and progression of EOC.
3.1. ROS and Oxidative Stress
ROS plays an important role in the normal female reproductive cycle, from affecting maturation of
the oocyte to ovulation, apoptosis of cells in corpus luteum, and embryo development [75]. Ovulation
results in increased levels of DNA amage in the FT epithelium at is likely a result of the ROS
generated during ovulation or the ovulation-associated increase in numbers of infiltrating macrophages
in the FT [17]. Additionally, during infection and inflammatory responses immune and damaged cells
produce ROS resulting in continuous exposure of the ovaries, FTs, and peritoneal cavity to ROS [76–78].
ROS exposure could potentially lead to epithelial cells in the ovary and FT undergoing transformative
changes, as has been demonstrated for ovarian surface epithelium cells grown in 3D culture [79].
Elevated ROS and RNS levels beyond the level that cells can neutralize results in OS. Increased OS
results in DNA damage, activation of signaling cascades, and epigenetic alterations.
DNA damage in a cell results in stimulation of DNA damage repair pathways. These repair
pathways can be inactivated or be erroneous, which results in increased genotoxic stress and mutated
DNA. Secretory tubal epithelial cells in the FT, a cell of origin for HGSC, are particularly susceptible to
genotoxic injury with persistent DNA damage that could lead to mutation and STIC formation [80].
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Mutations in tumor oncogenes and suppressors result in overexpression, constitutive activation of
the protein, loss of expression, or expression of nonfunctional proteins, resulting in a transformed cell.
Follicular fluid may have transformative properties as it has been demonstrated that bathing fimbriae
with follicular fluid containing high levels of ROS results in increased levels of DNA damage. Bathing
fimbriae that have loss of p53 and Rb with this follicular fluid results in evasion of apoptosis and cells
with persistent DNA damage [81].
ROS can activate pro-survival intracellular tyrosine phosphorylation signaling cascades, mainly
regulated by the MAPKs and redox sensitive kinases. Activation of c-Jun, JNK, ERK (extracellular
signal-regulated kinase), and p38-MAPK signaling cascades results in upregulation of cell cycle
proteins that enhances proliferation. Activation of JNK can also activate NF-κB, which can suppress
apoptosis. The MAPK pathway inhibits apoptosis and regulates differentiation. When activated in
transformed cells these pathways are important for tumor initiation. ROS affects redox sensitive
factors like thioreoxin, which is also found elevated in OC cell lines [82]. Thioredoxin is involved in
redox regulation of transcription factors such as NF-κB, NRF2, forkhead box class O (FOXO) proteins,
reducing factor-1 (ref-1), and hypoxia inducible factor (HIF-1α), thereby increasing their binding to
the DNA. Most of these transcription factors promote tumor growth and progression by regulating
expression of genes that affect cell survival and growth [83,84]. For example, FOXO, NRF2, and ref-1
transcription factors upregulate transcription of anti-oxidant proteins that scavenge free radicals and
allow survival of damaged or transformed cells [85]. HIF-1α upregulates the antiapoptotic factor,
bcl-2 as well as vascular endothelial growth factor (VEGF), a factor important for angiogenesis.
OS has also been shown to facilitate epigenetic mechanisms in many cancers, including EOC [86].
Innate immune-mediated inflammation drives epigenetic silencing of tumor suppressor genes
(TSGs) [87]. At sites of inflammation high levels of OS result in oxidative DNA damage that is
recognized by the mismatch repair proteins mutS homolog MSH2 and MSH6. MSH2 and MSH6 then
recruit epigenetic silencing proteins, including DNA methyltransferase 1 (DNMT1) to the sites of
damage [88]. In an in vivo model of inflammation-driven colon tumorigenesis this early recruitment
to sites of oxidative DNA damage results in permanent methylation of TSGs in tumors that form
at the sites of inflammation [89]. While such a mechanism has not been directly proven in EOC
models, Sapoznik et al. have demonstrated that exposure to follicular fluid or inflammation can
induce Activation-Induced Cytidine Deaminase (AIDS) in fallopian tube epithelial cells, which results
in epigenetic and genetic changes, increase in DNA damage and genotoxic stress and may be a
contributing factor to EOC [90].
3.2. TNF-α
The cytokine TNF-α plays an important role in the process of ovulation and in removal of
damaged corpus luteum. TNF-α ligand and its receptors, TNFRI and TNFRII are upregulated in
ovarian tumors compared to normal ovarian tissue and high levels of TNF-α are found in ascites from
OC patients [91–93]. OC cells have also been shown to secrete high levels of TNF-α as compared to
normal ovarian epithelial cells resulting in autocrine upregulation of TNF-α mRNA and in expression
of other pro-inflammatory cytokines, chemokines, and angiogenic factors like IL-6, M-CSF, CXCL2,
CCL2, and VEGF [93,94]. Kellie et al. have shown using mouse models that TNF-α stimulates
IL-17 production via TNFRI resulting in myeloid cell recruitment to the ovarian TME and increased
tumor growth [95]. TNF-α, also upregulates AIDS transcript levels which can contribute to genotoxic
stress [90].
3.3. IL-6
The cytokine IL-6 has been associated with poor survival in OC and is emerging as a potential
therapeutic target for EOC [67,68,96,97]. IL-6 is normally produced by ovarian epithelial and OC cells.
Macrophage migration inhibitory factor (MIF), EGF, and Transglutaminase secreted by OC cells can
stimulate IL-6 production via activation of NF-κB [98–100]. IL-6 increases proliferation of OC cells by
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facilitating their exit from G1 into S phase of the cell cycle and by activation of the MAPK-ERK-Akt
(protein kinase B) growth promoting signaling pathway [101]. ERK activation can promote formation
of ascites by increasing the migration of tumor cells [70]. IL-6 production by M2 macrophages present
in ascites in later stages of EOC can also stimulate cancer cell proliferation via STAT3 activation [102].
High levels of IL-6 can result in immune suppression by downregulation of IL-2, which stimulates Teff
cell production [103]. IL-6 also stimulates production of Metallomatrix proteins (MMPs) in OC cells,
which increases their invasive properties and promotes tumorigenesis [101,104].
3.4. IL-8
IL-8 a member of C-X-C chemokine family is present in the preovulatory follicle [105] where it
may play a role in increasing leukocyte infiltration [106]. It is also elevated in ovarian cysts and in
OC patients compared to healthy controls [107,108]. IL-8 has been found to be present in significantly
higher levels in the ascites of patients with OC in comparison to patients with benign gynecological
disorders [109]. Increased IL-8 expression has been associated with poor prognosis in OC patients [107].
Treatment of EOC cells with IL-8 results in their increased proliferation, which is accompanied by an
increase in cyclins B1 and D1 and is dependent on phosphorylation of Akt and ERK [110]. Cyclins B1
and D1 are important for cell cycle progression, and an increase in their expression leads to increased
cell growth. On the other hand, two independent studies have demonstrated that IL-8 inhibits EOC
growth by increasing neutrophil infiltration [111,112].
3.5. Lyophosphotidic Acid (LPA)
LPA is a phospholipid that binds to and activates the endothelial differentiation gene (Edg) family
of receptors. LPA is present in ovarian follicular fluid and it stimulates IL-6 and IL-8 production in the
corpus luteum [113,114]. OC cells have been shown to produce LPA, which functions like a growth
factor [115–119]. Plasma and ascites of OC patients have elevated levels of LPA that contribute to OC
progression via upregulation of COX-2 and MMP2 [115,120,121]. LPA can bind to LPA2 receptor and
induce expression of IL-6 and IL-8 via activation of NF-κB and AP-1 in OC cell lines [122]. It can induce
ROS dependent Akt and ERK phosphorylation and inhibition of LPA can increase apoptosis of EOC
cells [123]. ERK phosphorylation can induce phosphorylation of HIF-1α, which then can upregulate
VEGF and promote tumorigenesis. Another group demonstrated that stimulating EOC cells with
ether-linked LPA resulted in their increased proliferation and survival by increased synthesis of DNA
and activation of Akt via PI3K, which contributes to tumor progression [124].
3.6. Prostaglandins and COX-1 and COX-2
Prostaglandins are secreted in the ovary, FT, and uterus. They are important for maturation
of the oocyte and facilitate the movement of the FT so that the mature oocyte can move from the
ovary to the uterus. In the uterus prostaglandins help regulate and maintain uterine blood flow.
COX-1 and COX-2 are enzymes that catalyze the production of prostaglandins from arachidonic
acid and are overexpressed in OC patients [22,125,126]. High COX levels positively correlate with
increased cell proliferation, angiogenesis, and malignancy in ovarian tumors [126,127]. COX-1 and
COX-2 are normally involved in the acute inflammatory response but can become dysregulated in
chronic inflammatory or TMEs. Obermajer et al. have demonstrated that prostaglandins produced
by COX-2 can stimulate production of CXCR4 and its ligand Stromal cell derived factor 1 (SDF1)
CXCL12 in myeloid derived suppressor cells (MDSC), which stimulates them to migrate towards
OC ascites [128]. MDSCs inhibit the proliferation and differentiation of T cells, resulting in overall
immune suppression, which allows the tumor cells to escape immune surveillance and continue to
grow. Genetically engineered mouse models of EOC; one harboring the p53 and Rb deletion and other
the KRASG12D mutation and Pten deletion, demonstrate increased COX-1 levels, thus suggestive that
COX-1 could be used as a potential biomarker and therapeutic target for EOC [129]. Further when
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COX-1 was inhibited in EOC cells, it led to reduction in prostacyclin (a type of prostaglandin) synthesis
and reduced tumor growth by enhanced apoptosis [130].
4. Inflammation and EOC Angiogenesis
Angiogenesis is required for the growth of both primary and metastatic tumors [131]. The process
of angiogenesis is a complex multi-step process reviewed previously [132]. It is regulated by a balance
between pro-angiogenic and antiangiogenic factors. Hypoxic and ischemic areas are present at sites
of inflammation and also in tumors mainly due to obstruction of local blood vessels, differences
in pace of growth of blood vessels and growth of the tumor and/or infiltration of immune cells.
Macrophages accumulate at hypoxic sites and alter their gene expression profiles in response to the
hypoxic conditions. One of the important genes for angiogenesis that is upregulated by hypoxia is
VEGF [133,134]. The rate-limiting step in angiogenesis is VEGF signaling in endothelial cells (ECs) [135].
VEGF functions via tyrosine kinase receptors VEGF-1 and VEGF-2 and promotes migration, survival,
proliferation of ECs, and formation of new blood vessels [136–138]. Many of the inflammatory
mediators discussed so far are also involved in promoting angiogenesis in EOC as detailed below
(Figure 2, Table 1).
4.1. TNF-α
TNF-α creates a pro-inflammatory TME and has also been associated with promoting angiogenesis.
It has been hypothesized that TNF-α induces the production of soluble factors that promote tumor
angiogenesis. Culture supernatants from TNF-α expressing cells induce the growth of mouse
lung endothelial cells in vitro while culture supernatants from TNF-α lacking cells do not exert
the same effect [94]. In pituitary adenomas TNF-α is known to induce VEGF that in turn induces
CXCL12 [139,140]. VEGF and CXCL12 synergistically induce angiogenesis in EOC [141]. Mice injected
with OC cells lacking TNF-α have reduced vascular density in their tumors and reduced formation of
blood vessels in the peritoneal deposits. These mice also did not have accumulation of ascetic fluid
suggesting the importance of TNF-α in angiogenesis and EOC progression [94].
4.2. IL-6
In physiological conditions, IL-6 is involved in angiogenesis in the ovary during the development
of ovarian follicles [142]. IL-6 induces the phosphorylation of STAT3 and MAPK in ovarian endothelial
cells thereby enhancing their migratory ability, a key step in angiogenesis [143]. As explained before,
OC cells also secrete increased amounts of IL-6. Some OC cells also secrete an alternative splice variant
of IL-6Rα, the soluble form sIL-6R, which consists of only the ectodomain of the transmembrane
receptor. By a process called trans-signaling, the sIL-6R-IL-6 complex initiates signaling in cells in the
ME that do not express the transmembrane receptor facilitating angiogenesis [144].
4.3. IL-8
Several studies have clearly established the role of IL-8 in promoting angiogenesis. Hu et al.,
demonstrated that IL-8 plays a role in angiogenesis using a rat sponge model [145]. IL-8 was also
able to induce angiogenesis in the rat cornea, which is normally avascular [146]. As explained in
the previous section, there are several sources of IL-8 in ovarian TME. Overexpression of IL-8 in
A2780 (non-IL-8 expressing) OC cells has been shown to increase the expression of VEGF, MMP-2,
and MMP-9; while depletion of IL-8 in SKOV3 (IL-8 expressing) cells has been shown to reduce VEGF,
MMP-2, and MMP-9 [110]. The process of angiogenesis involves degradation of extracellular matrix
components and proliferation and migration of endothelial cells. MMPs are a family of endopeptidases
that breakdown components of extracellular matrix and have been implicated in angiogenesis [147].
Because of the importance of VEGF and MMPs in angiogenesis these findings suggest that IL-8 in the
ovarian TME will promote the formation of new blood vessels in EOC. Targeting IL-8 using mouse
models reduces EOC growth and decreases angiogenesis [112].
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Table 1. Role of inflammatory mediators in different stages of tumor progression.
Inflammatory
Mediators Secreting Cell Type
Stages in Tumor Progression





↑ autocrine production of
TNF-α and IL-6, M-CSF,
CXCL2, CCL2 [93,94] and AIDS
mRNA level [90]
↑ VEGF, VEGF↑ CXCL12
and promotes
angiogenesis [139–141]
↑ TGF-α secretion by stromal
fibroblasts which promote
peritoneal metastasis [148]







↑Proliferation by promoting G1
to S transition and MAPK-ERK-
Akt activation and STAT3
activation [101,102]





of endothelial cells [143]
sIL-6R-IL-6 facilitates
angiogenesis in cells
lacking IL-6 receptor [144]
Stimulates production of MMPs
in OCs which ↑ invasion and
migration [101,104] ↑ IL-6 in
ascites enhances invasion via
JAK-STAT signaling [151]
↓ Caspase- 3 cleavage and
makes OC cells resistant
to cisplatin and paclitaxel
[152] ↑Expression of
MDR1, GSTpi, Bcl-2,
Bcl-xL, and XIAP [152]
IL-8 Pre-ovulatory follicles,OC cells, ascites
↑ Proliferation by ↑ cyclin B1
and cyclin D1 via pAkt [110]









LPA Follicular fluid, corpusluteum, OC cells, ascites
↑ IL-6 and IL-8 via NF-κB and
AP-1 [113,114,122] ↑COX-2
AND MMP2 [115,120,121] ↑
phosphorylation of Akt and
ERK resulting in increased cell
cycle [123,124]
↑ Expression of VEGF via
Myc and Sp-1 [155]





COX-1 and COX-2 Ovary, FT, uterus, MDSCs
↑ CXCR4 and SDF1 in MDSCs
resulting in immune
suppression [128]
↑ Bcl-2 and blood vessel
formation [158,159]
↑ Bcl-2, thus inhibiting
apoptosis in lung, colon,
breast and prostate
cancers [158,159]
TGF-β and EGF OC cells, CAFs
TGF-β ↑ VCAN, which
activates NF-κB and
↑MM-9 [160]
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4.4. LPA
In addition to playing a role in initiation, and progression, LPA has also been implicated in
angiogenesis in OC. LPA has been shown to induce transcriptional activation of VEGF in EOC cell
lines [163]. Transcriptional activation of VEGF primarily occurs through HIF-1α under oxygen limiting
conditions in Hep3B hepatocellular carcinoma cells [164]. LPA mediated induction of VEGF expression
has been shown to be independent of HIF-1α in EOC cell lines. Transition metal cobalt treatment also
leads to stabilization of HIF1α similar to hypoxia. Combination treatment of EOC cells with cobalt
and LPA additively increased VEGF production suggesting the effect of two different pathways [155].
LPA activates c-Myc and Sp-1, which induce VEGF expression through consensus binding sites in the
VEGF promoter that have been implicated in HIFα independent induction of VEGF [155].
5. Inflammation and EOC Metastasis
Tumor metastasis is the major cause of mortality in most cancers, including EOC. Most EOC
patients are diagnosed at an advanced stage when the cancer has already metastasized [165].
Dissemination of cancer cells to distant sites is a complex multi-step process called the
invasion-metastasis cascade and is reviewed in detail in previous papers [166–168]. Briefly, some major
steps in metastasis are—invasion through the basement membrane, intravasation into the lymphatics
and circulation, survival of disseminating cancer cells in circulation, extravasation into surrounding
tissues, colonization, and finally, formation of micro and macro metastases. However, unlike other
epithelial malignancies, EOC has a different pattern of metastasis. EOC cells directly shed from the
primary tumor into the peritoneal space and disseminate to organs in the peritoneal cavity. One of the
prerequisites for cancer cells to metastasize is to undergo a process called epithelial to mesenchymal
transition (EMT) where they lose their ability to attach to the basement membrane and acquire
a mesenchymal phenotype and characteristics. Several recent evidences have indicated that the
TME aids tumor cells to acquire these properties facilitating the metastatic cascade. An example of
the ME promoting metastasis is the presence of STICs in the distal part of the FT, which shares
its ME with ovary. Yang-Hartwich et al. have demonstrated that granulosa cells in the ovary
secrete SDF-1 (stromal cell-derived factor 1) [169]. SDF-1 functions as a chemoattractant and recruits
malignant FT cells to the ovary suggesting that the ovary is a primary site of metastasis, not the
primary tumor site. Russo et al. demonstrated that loss of PTEN (phosphatase and tensin homolog)
by the malignant FT cells and upregulation of WNT4 (wingless-related MMTV integration site 4)
is crucial for initial metastasis to the ovary thereby supporting the tubal origin of EOC and the
ovary as the primary site of metastasis [170]. The cells that make up the TME also secrete various
inflammatory mediators, which facilitate progression and metastasis of OC cells (Figure 2, Table 1).
These factors enable tumor metastasis by deregulating signal transduction pathways. Examples include
the PI3-Akt and RAS-ERK pathways, which control migration and invasion through downstream
effectors like Rho family GTPases, extracellular proteases, integrins, matrix associated proteins like
focal adhesion kinases (FAK), and transcription factors like ETS2 and AP-1 [171–173]. Robinson-Smith
et al. demonstrated that peritoneal inflammation correlated with dissemination of cancer cells from the
ovaries in SCID mice. Augmenting the inflammatory response using thioglycolate accelerated ascites
formation and metastasis while suppressing the inflammation using acetyl salicyclic acid impeded
ascites formation and reduced metastasis. This inflammation-induced metastasis of OC cells was
found to be primarily mediated by macrophages and not neutrophils or NK cells [174]. As explained
in one of the previous sections a pro-inflammatory environment can be created in the peritoneum
due to secretion of cytokines like IL-6 and TNF-α by adipose cells [31]. Omentum, the primary site of
metastasis of OC, is largely composed of adipose cells. In addition to adipocytes, omentum also consists
of blood and lymph vessels, immune cells, and stromal cells [175]. Adipocytes have been shown to
increase migration, invasion, and proliferation of EOC cells. Upregulation of SUSD2 a secreted tumor
suppressor by adipocytes by guadecitabine treatment reduced EOC migration and invasion. This
finding suggests that epigenetic changes in the stromal cells in addition to EOC cells can facilitate EOC
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metastasis [176]. Omentum has aggregates of immune cells around the vasculature commonly referred
to as milky spots [177]. Melanoma, lung carcinoma, ovarian carcinoma, and mammary carcinoma
cell lines have been shown to specifically metastasize to the immune cell aggregates in the omentum
when injected intraperitonealy into C57BL/6 mice [178]. These milky spots in the omentum have
also been shown to facilitate metastatic colonization of the OC cells. Clark et al. have suggested that
both adipocytes and milky spots have specific and important roles in metastatic colonization of OC
cells [179]. These evidences imply that omentum potentially provides a good niche for the growth of
ovarian cancer cells. Here we will specifically discuss how inflammatory mediators promote tumor
metastasis in EOC.
5.1. ROS
EOC cells produce a large amount of ROS [180]. Loss of E-cadherin is one of the characteristic
features of tumor cells with increased ability to migrate and invade. Wang et al. demonstrated that
ROS leads to HIFα mediated activation of lysl oxidase. Lysl oxidase was shown to inversely correlate
with E-cadherin expression promoting migration and invasion in EOC cells [181]. Tumor cells treated
with sub-lethal doses of H2O2 failed to attach to the extracellular matrix components fibronectin and
laminin and had increased metastatic colonization of lung, thereby establishing a role for ROS in tumor
cell metastasis [182].
5.2. TNF-α
TNF-α provides a good example of how interactions between cancer and stroma aid in OC
metastasis. Ascitic fluid and OCs contain a large number infiltrating macrophages in part because
OCs constitutively produce M-CSF, which functions as a chemoattractant for monocytes [183].
These infiltrating monocytes produce many cytokines one of which is TNF-α [184,185]. OC cells also
have elevated TNF-α expression that is regulated by DNA hypomethylation and chromatin remodeling
of the TNF-α promoter. Increased TNF-α produced by OC cells and macrophages stimulates increased
expression of TGF-α in stromal fibroblasts. TGF-α secreting stromal fibroblasts promote peritoneal
metastasis of OC via EGF receptor signaling [148].
Furthermore, in EOC cells and clinical biopsies TNF-α expression correlates with one of the most
commonly expressed cytokine receptors CXCR4. TNF-α stimulation of EOC cells enhanced their
migration toward the only CXCR4 ligand, CXCL12. Stimulation of EOC cells by CXCL12 induced
mRNA and protein expression of TNF-α. Therefore, a positive feedback loop has been suggested
where in CXCL12 induced TNF-α potentially acts on the cancer cells and induces CXCR4 expression
thereby enhancing tumor cell migration [149,150].
5.3. IL-6
IL-6 has also been implicated in metastasis of OC. Elevated levels of IL-6 found in serum and
peritoneal fluid of EOC and OC patients have many sources [186–188]. Mesothelial cells in the
peritoneum, TAMs, and EOC cells all secrete IL-6 [67]. M2 polarized macrophages in the ovarian
TME induce proliferation and invasion of EOC cells by secretion of IL-6 [189]. Increased IL-6 present
in ascites from OC patients enhanced the invasive ability of OC cells via the JAK-STAT signaling
pathway. Canonically IL-6 signaling occurs by binding of the ligand to its transmembrane receptor
IL-6Rα. The effect of IL-6 on invasion of OC cells correlated with their IL-6R expression [151]. Because
through trans-signaling, the sIL-6R–IL-6 complex initiates signaling in cells that do not express the
transmembrane receptor [144], we hypothesize that IL-6 produced by macrophages could also promote
invasion of OC cells similar to the mechanism of induction of angiogenesis.
5.4. IL-8
Increased proliferation, anchorage independent growth, and angiogenic potential are some
prerequisites for cells to metastasize. IL-8 increases the proliferation of OC cells and upregulates VEGF
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and MMP2 and 9 via activation of NF-κB, which results in enhanced invasive phenotype of OC cells.
IL-8 has been shown to activate TAK1/NF-κB signaling via CXCR2, thereby facilitating the seeding
and growth of OC cells in the peritoneal cavity during metastasis [153].
5.5. LPA
LPA promotes proliferation, survival, and metastasis of EOC cells by inducing the expression of
c-Myc, VEGF, IL-8, MMPs and COX-2 [163,190–193]. LPA acts through its receptors LPAR1-3, which are
members of G-protein coupled receptor superfamily. Invasive EOC cells have significantly higher
expression of LPAR1 in comparison to non-invasive cell lines and LPA induces EOC cell invasion
specifically through LPAR1 and not through LPAR2 or LPAR3 [194]. It can also induce secretion
of urokinase in EOC cells, which has been shown to play a role in metastasis and its high levels
correlate with advanced OC and poor survival in patients. LPA has been shown to increase promoter
activity, mRNA levels, protein levels, and enzyme activity of Urokinase plasminogen activator (uPA)
possibly via the edg-4 LPA receptor [156]. uPA is involved in converting plasminogen to plasmin,
which facilitates the degradation of basement membrane and extracellular membrane proteins like
fibronection aiding in metastasis [157].
5.6. TGF-β
TGF-β initiates signaling by dimerization of serine/threonine kinase receptors. The dimerization
of receptors results in their phosphorylation, which then relays signals downstream via SMAD
dependent and SMAD independent pathways. Phosphorylation by the TGF-β receptor causes
R-SMADs to bind to Co-SMAD and translocate to the nucleus, where they activate transcription
of genes that promote invasion, migration. Bone morphogenic proteins (BMPs) are cytokines that
belong to TGF-β family and have been associated with progression of many different cancer types.
Their mechanism of promoting tumor progression depends on the TME in which the cancer grows
and their mode of metastatic spread [195]. Specifically, BMP-2 overexpression has been associated
with poor prognosis in OC [196]. Additionally, TGF-β could potentially modify the TME to promote
tumorigenesis. Veriscan (VCAN), an extracellular matrix associated protein, was upregulated by TGF-β
through TGF-β receptor II (TGFBR2) and SMAD signaling making the EOC cells more aggressive.
Increased VCAN expression enhanced motility and invasion of EOC cells by activating NF-κB signaling,
increased expression of MMP-9, and hyaluronidase mediated motility receptor [160]. CAFs have higher
expression of TGF-β receptors in comparison to normal ovarian fibroblasts and EOC cells suggesting
that CAFs within the TME are more responsive to TGF-β then the other cell types [160].
6. Inflammation and EOC Chemoresistance
The standard treatment for EOC patients is cytoreductive surgery followed by platinum/
taxane-based chemotherapy [197]. The main obstacle in treatment of EOC patients is development
of chemoresistance. Resistance to chemotherapy can be either intrinsic or acquired. Inherent gene
expression patterns harbored by chemo-naïve tumor cells contribute to intrinsic resistance. Acquired
resistance is a consequence of different alterations induced after exposure to chemotherapeutic
agents [198]. Different mechanisms, including increased drug efflux, decreased uptake of the drug,
inactivation of the drug, increased DNA repair, and reduced apoptotic response, have been implicated
in development of platinum resistance [199]. Several recent studies have demonstrated that the TME
contributes to both intrinsic and acquired resistance. One type of intrinsic drug resistance influenced
by the TME is referred to as environment mediated drug resistance (EMDR). In EMDR, factors and
cells present in the TME activate diverse signaling events, transiently protecting the tumor cells
from undergoing apoptosis in response to chemotherapeutic agents [200,201]. Another type of drug
resistance induced by cytokines, chemokines, and growth factors secreted by fibroblast cells in the
tumor stroma is called soluble factor mediated drug resistance (SFM-DR). A good example of SFM-DR
is IL-6 mediated drug resistance in multiple myeloma. IL-6 is important for growth of multiple
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myeloma cells. IL-6 activates STAT3 signaling in these cells and protects them from Fas mediated
apoptosis by upregulating antiapoptotic protein Bcl-XL [202]. Myeloma cells that produced IL-6 in
an autocrine manner were found to be resistant to dexamethasone induced apoptosis while non-IL-6
producing cells were sensitive [203]. Cell adhesion mediated drug resistance (CAM-DR) occurs due to
adhesion of tumor cells to extracellular matrix components like laminin, collagen, and fibronectin or
due to fibroblasts present in the tumor stroma [204]. An example of this type of resistance is when drug
sensitive myeloma cells were adhered to an extracellular matrix component fibronectin, they exhibited
a reversible drug resistant phenotype which was not due reduced drug accumulation or increase in
antiapoptotic proteins like Bcl-XL [201]. Here we will discuss specific inflammatory mediators and
their role in OC chemoresistance (Figure 3).
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6.1. ROS
R S are abundant in the pro-inflammatory TME. Malignant EOC tissues have been shown
to have 96% higher ROS levels than normal controls [205]. OC stem like cells or OCICs are more
drug resistant and responsible for relapse of chemoresistant tumors [66]. OCICs produce ROS and
superoxide. This ROS induces the expression of peroxiso e proliferator-activated receptor-ga a
coactivator (PCG)-1α, hich regulates itochondrial biogenesis and is required for expression of
detoxifying enzy es [206,207]. PCG1α increases the aldehyde dehydrogenase (ALD ) activity and
expression of ultidrug resistance gene ( DR1). DR1 is an ATP dependent transporter that has
been associated with efflux of platinum based drugs from OC cells contributing to platinum resistance.
Scavenging ROS reduced expression of PCG1α and drug resistant related genes thereby linking ROS
to development of chemoresistance [207].
. . I -6
I - in the OC TME is associated with increased chemoresistance. Wang et al. demonstrated
that autocrine production of IL-6 by EOC cells makes them resistant to cisplatin and paclit xel by
causing ecreased prot olytic cleavage of capase-3. Paclitaxel resistant EOC cells have increased
expression of IL-6 and one of i s downstream effectors STAT3 [208,209]. IL-6 producing OC cells also
had increased expression of multidrug resista t genes MDR1 and GSTpi and anti-apoptotic genes
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Bcl-2, Bcl-xL, and XIAP, suggesting that IL6 promotes drug resistance by increasing drug efflux and
reducing apoptosis [152].
6.3. IL-8
IL-8 blocks TRAIL-induced apoptosis and reduces caspase cleavage in EOC cell lines by decreasing
the expression of death receptor (DR) 4 [210]. TRAIL is a cell death inducing ligand that belongs to
the TNF superfamily and has been shown to induce apoptosis specifically in tumor cells and not in
nontransformed cells [211,212]. Combination of TRAIL and the chemotherapeutic drugs—cisplatin,
doxorubicin, and paclitaxel has been shown to induce apoptosis in chemoresistant EOC cell lines by
causing increased caspase and PARP cleavage [154]. This finding suggests that IL8 may contribute to
chemoresistance by blocking TRAIL.
6.4. LPA
LPA has been shown to contribute to platinum resistance by preventing cells from undergoing
cisplatin-induced apoptosis without affecting their proliferation rate. The mechanism of how LPA
inhibits apoptosis in EOC cells in response to cisplatin is not yet clearly understood [161].
6.5. TGF-β and EGF
Recurrent OC show significantly higher expression of TGF-β1 and TGF-β3 in comparison to
primary tumors and normal ovary tissue [213]. Inhibition of TGF-β by the inhibitor LY2109761
sensitizes resistant SKOV3 cells to cisplatin suggesting that TGF-β contributes to the development
of platinum resistance in EOC cells [162]. Cisplatin resistant A2780P cells had hypomethylation
and upregulation of TGFBR2 confirming the involvement of the pathway in acquisition of platinum
resistance [214]. An elevated level of EGF receptor (EGFR) has also been associated with poor prognosis
in OC patients [215]. EGF has been shown to stimulate the growth of EOC cells expressing EGFR and
alters their cell cycle distribution [216]. EGF similar to LPA has been shown to protect EOC cells from
undergoing cisplatin induced apoptosis [161].
6.6. COX-2
In addition to being associated with tumor initiation and progression, COX-2 has also been
associated with chemoresistance. Ferrandina et al. reported that a statistically significant higher
percentage of primary OC patients unresponsive to platinum-containing chemotherapy were positive
for COX-2 than responsive patients (84.6% versus 34.6%, respectively) [217]. The percentage of positive
COX-2 staining per tumor area in COX-2 positive patients ranged from 15 to 45%. The results from
this study suggest that COX-2 levels may influence the response of patients to different chemotherapy
regimens, but the sample size of this study was small and the results need to be confirmed in a larger
group of patients. Furthermore, this association needs to be corroborated biochemically [217]. In both
patients groups undergoing cytoreductive surgery and explorative laparotomy, COX-2 expression was
higher in nonresponders [218]. Using lung, colon, and prostate cancer models, COX-2 has been shown
to induce Bcl-2 and promote tumor growth by facilitating the formation of new blood vessels [158,159].
These findings suggest that COX-2 may contribute to chemoresistance by inhibiting apoptosis and
promoting angiogenesis in OC as well.
7. Treatment Strategies Targeting Inflammatory Mediators in EOC
As discussed, development of resistance to available chemotherapeutic drugs remains the major
obstacle in management of OC patients. While several immunotherapies have been developed to
improve the antitumor response of T-cells and/or modulate the immune response, here we will
discuss EOC treatment strategies that specifically target the inflammatory mediators that have been
reviewed above.
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A monoclonal antibody directed at VEGF, bevacizumab, has been widely studied and is a
promising target in EOC [219]. Bevacizumab is a recombinant humanized monoclonal antibody and
has been approved by the FDA for treatment of metastatic breast, non-small cell lung, and colorectal
cancer. Phase II clinical studies have shown that it is active in treatment of recurrent OC patients [220].
OCEANS trial was a randomized phase III clinical trial that evaluated the safety and efficacy of
bevacizumab in combination with gemcitabine and carboplatin (GC) in comparison with GC alone
in recurrent platinum sensitive ovarian, primary peritoneal, or FT cancer. This trial demonstrated
that bevacizumab was able to prolong the PFS in platinum-sensitive recurrent EOC patients [221].
In addition to OCEANS, GOG218, and ICON7 have also shown that bevacizumab prolongs the PFS in
OC patients confirming the promise this therapeutic target holds for management of OC [222,223].
We have discussed some mechanisms by which the pro-inflammatory cytokine TNF-α promotes
OC metastasis and angiogenesis making it a good target for development of therapeutic agents.
The safety profile and biological activity of a monoclonal anti-TNF-α antibody, Infliximab was assessed
in a clinical study consisting of patients with advanced solid tumors, including OC. Infliximab
did not have any toxic effects and was well tolerated by these patients. Reduced plasma levels
of IL-6 and CCL12 in these patients was observed 24 h and 48 h after administration of Infliximab,
while neutralization of TNF-α was detected after an hour indicating some biological activity [224].
This response warrants further study of Infliximab as a therapeutic agent for treatment of OC.
IL-6/STAT3 signaling has been implicated at different stages of OC progression and is a promising
target although most agents are still in preclinical or early clinical trial stages. Siltuximab, an anti-IL-6
antibody, suppresses IL-6-induced STAT3 phosphorylation and nuclear translocation in OC cell lines.
Siltuximab treatment also reduced the level of pro-survival proteins like Bcl-XL and Survivin, which are
downstream of STAT3. Siltuximab was able to sensitize paclitaxel resistant OC cell lines, but did not
show the same effect in vivo [225]. sc144 is a novel small molecule inhibitor has shown significant
promise in preclinical studies. sc144 binds gp130, which is a signal transducer in STAT3 signaling.
It causes phosphorylation of gp130 leading to its deglycosylation. This abrogates downstream STAT3
phosphorylation and nuclear translocation inhibiting transcription of downstream genes. sc144
has increased potency in EOC cells in comparison to normal epithelial cells and slows down the
growth of tumors in xenograft models of EOC [226]. A phase I clinical trial combining carboplatin,
the monoclonal antibody Tocilizumab, which blocks IL-6R, and immune enhancer INF-α showed good
promise. The EOC patients who received the highest dose of Tocilizumab had increased serum levels
of IL-6 and sIL-6R and also showed longer median overall survival [227].
We have discussed the role of TGF-β in EOC tumor progression substantiating it as a good
therapeutic target. A preclinical study of LY2109761 (TGFβRI and TGFβRII kinase inhibitor) in
combination with cisplatin was conducted by Gao et al. This inhibitor significantly increased apoptosis
in cisplatin resistant cells. Combining LY2109761 with cisplatin had antiproliferative effects and
increased the rate of apoptosis in parental and cisplatin resistant xenograft models [162]. In triple
negative breast cancer, LY2157299 a TGF-β1 receptor kinase inhibitor, prevented recurrence of tumors
in xenograft models after treatment with paclitaxel [228]. Early phase clinical trials of LY2157299 in
patients with advanced or metastasized pancreatic cancer have been completed. Early phase trials
in triple negative metastatic breast cancer, unresectable hepatocellular carcinoma, and metastatic
castration resistant prostate cancer are underway [229].
EGF has also been associated with chemoresistance in EOC. Cetuximab, a chimerized monoclonal
antibody that targets EGFR, was tested in combination with carboplatin in patients with recurrent
platinum sensitive OC. Cetuximab showed modest activity in these patients [230]. Panitumumab,
a human monoclonal antibody specific to EGFR, in combination with carboplatin did not improve
efficacy or progression free survival in platinum sensitive EOC patients [231].
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8. Conclusions and Future Perspectives
Several studies in the last decade have associated increased inflammation and inflammatory
mediators with increased EOC risk and reduced survival in EOC patients. We have presented
published evidence suggesting that inflammation and inflammatory mediators promote ovarian
tumorigenesis. However the mechanisms by which the process of inflammation culminates in ovarian
tumor initiation need to be further understood. Such links have been established in colon and
pancreatic cancer. Understanding these mechanisms is important for developing ways to target
inflammatory mediators and reduce OC risk. Furthermore, epidemiological studies of NSAIDs and
early clinical trials targeting IL-6 and TNF-α have shown significant promise, thus suggesting that
targeting inflammatory mediators as treatment for OC warrants future research.
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